BioStock: Abliva’s presence is felt at Euromit

Held every three years, the Euromit meeting is happening this week in Bologna, Italy. Abliva, having now initiated their phase II FALCON study  in patients with primary mitochondrial disease, is attending the meeting this week.  The team will be presenting their research findings and engaging with experts in the field, further showcasing their commitment to advancing mitochondrial research and bringing innovative therapies to patients. BioStock contacted Abliva’s Chief Medical Officer, Magnus Hansson, to learn more.

Read the article at biostock.se:

https://www.biostock.se/en/2023/06/ablivas-presence-is-felt-at-euromit/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/